COVID-19 updates - Get the latest information about Coronavirus and Iowa Heart Center


Purpose of Study

Evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality (cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction (MI) and non-fatal stroke) in subjects with a documented recent ACS and the AA genotype at variant rs 1967309 in the ADCY9 gene.

Trial Status

In Follow up

Eligibility Criteria

Are at least 45 years old, have had a heart attack within the past 3 months, and have the AA genotype.

Duration of Participation

Approximately 54 months

Contact Name: Research Department

Contact Phone: 515-633-3842